Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Accounts Payables (2023 - 2025)

Telix Pharmaceuticals has reported Accounts Payables over the past 3 years, most recently at $150.3 million for Q4 2025.

  • Quarterly Accounts Payables rose 64.3% to $150.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $150.3 million through Dec 2025, up 64.3% year-over-year, with the annual reading at $150.3 million for FY2025, 73.23% up from the prior year.
  • Accounts Payables was $150.3 million for Q4 2025 at Telix Pharmaceuticals, up from $91.5 million in the prior quarter.
  • Over five years, Accounts Payables peaked at $150.3 million in Q4 2025 and troughed at $21.4 million in Q4 2023.
  • The 3-year median for Accounts Payables is $91.5 million (2024), against an average of $87.7 million.
  • Year-over-year, Accounts Payables skyrocketed 328.07% in 2024 and then surged 64.3% in 2025.
  • A 3-year view of Accounts Payables shows it stood at $21.4 million in 2023, then surged by 328.07% to $91.5 million in 2024, then surged by 64.3% to $150.3 million in 2025.
  • Per Business Quant, the three most recent readings for TLX's Accounts Payables are $150.3 million (Q4 2025), $91.5 million (Q4 2024), and $21.4 million (Q4 2023).